Avadel Pharmaceuticals (AVDL) to Release Earnings on Monday

Avadel Pharmaceuticals (NASDAQ:AVDL) is expected to issue its Q4 2025 results before the market opens on Monday, March 2nd. Analysts expect the company to announce earnings of $0.09 per share for the quarter. Investors may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Wednesday, March 11, 2026 at 4:00 PM ET.

Avadel Pharmaceuticals Trading Down 1.1%

Shares of AVDL opened at $21.39 on Monday. Avadel Pharmaceuticals has a 52 week low of $6.38 and a 52 week high of $23.57. The stock has a 50 day moving average of $21.51 and a 200-day moving average of $18.73.

Analysts Set New Price Targets

Several analysts have weighed in on the stock. UBS Group lowered shares of Avadel Pharmaceuticals to a “neutral” rating in a research note on Tuesday, October 28th. Zacks Research raised shares of Avadel Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Tuesday, January 6th. Wells Fargo & Company increased their price objective on shares of Avadel Pharmaceuticals from $20.00 to $22.50 and gave the stock an “equal weight” rating in a research note on Thursday, November 20th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Avadel Pharmaceuticals in a report on Monday, December 29th. One analyst has rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Avadel Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $20.00.

Institutional Investors Weigh In On Avadel Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the business. Russell Investments Group Ltd. grew its holdings in Avadel Pharmaceuticals by 8.3% in the 4th quarter. Russell Investments Group Ltd. now owns 12,625 shares of the company’s stock worth $272,000 after buying an additional 967 shares in the last quarter. Creative Planning boosted its position in Avadel Pharmaceuticals by 10.0% during the 2nd quarter. Creative Planning now owns 19,376 shares of the company’s stock worth $171,000 after acquiring an additional 1,759 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Avadel Pharmaceuticals by 4.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 54,885 shares of the company’s stock worth $430,000 after purchasing an additional 2,291 shares in the last quarter. Legal & General Group Plc grew its stake in shares of Avadel Pharmaceuticals by 1.9% in the third quarter. Legal & General Group Plc now owns 125,899 shares of the company’s stock worth $1,922,000 after purchasing an additional 2,361 shares in the last quarter. Finally, Franklin Resources Inc. increased its holdings in shares of Avadel Pharmaceuticals by 4.4% during the fourth quarter. Franklin Resources Inc. now owns 58,821 shares of the company’s stock valued at $1,268,000 after purchasing an additional 2,465 shares during the period. Institutional investors own 69.19% of the company’s stock.

Avadel Pharmaceuticals Company Profile

Avadel Pharmaceuticals plc is a global specialty biopharmaceutical company focused on developing and delivering treatments for rare diseases and central nervous system disorders. Headquartered in Dublin, Ireland, with operations in the United States, Avadel’s portfolio centers on sleep disorder therapeutics, including its flagship low-sodium oxybate product, XYWAV, which is approved in the U.S. for the treatment of cataplexy or excessive daytime sleepiness in patients with narcolepsy. The company is also advancing FT218, a once-nightly formulation of sodium oxybate, currently under regulatory review for narcolepsy management.

Formed through a rebranding of Flamel Technologies in 2016 and a strategic shift toward rare disease drug development, Avadel has built its R&D capabilities around improving patient compliance and reducing daily sodium exposure compared to traditional therapies.